- Biological Inventions
- Brand Valuation
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB Decisions
- Legal Issues
- Media & Entertainment Law
- News & Updates
- Patent Act
- Patent Commercialisation
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Section 3(D)
- Social Media
- Sports Law
- Telecom Law
- Trademark Litigation
The Bombay High Court, on April 20, 2021, through the Division bench of J. Nitin Jamdar and J. C.V. Bhadang, presided over the matter of Cutis Biotech v. Serum Institute of India Pvt. Ltd. The two pharmaceutical companies manufactured vaccines for COVID-19, titled ‘Covishield’, and therein, both had applied for registering this trademark, whose applications were pending. Cutis Biotech, in the protection of the stated mark, filed a Commercial suit in the Court Court at Pune, seeking an interim injunction to restrain Serum Institute from using the said mark.
Before delving into the decisions passed by the District Court and subsequently, by the Bombay High Court, it is pertinent to observe the principles and niches of law applied by the two benches.
Section 27(1) of the Trademarks Act, 1999 states that no person shall be entitled to institute any proceeding to prevent or recover damages for the infringement of an unregistered trademark. However, sub-section 2 of the same provides that in these situations, the aggrieved has the right to take action against any person for passing off his goods or services as the goods and services of the applicant and preserves the remedies to prevent passing off actions. In the present situation, it was observed that since neither Cutis Biotech (hereinafter, the Applicant) nor Serum Institute (hereinafter, the Respondent) had registered trademarks, the matter was adjudicated based on the tort of passing off.
The tort of passing off, based on the principle of equity, prevents unscrupulous persons from benefiting from the reputation and goodwill earned by an honest business, and the injunction granted thereof ensures compliance with the same. The applicant must establish the following three factors to suffice a case of passing off:
- Goodwill and reputation attached to his/her goods and services;
- Respondent’s acts will likely lead the public to believe that the goods and services offered by the respondent are goods and services of the applicant;
- Damage suffered or likely to be suffered because of the said passing off.
Observing the above-stated law, and the facts in question, the District Court rejected the Interim Application on the following grounds:
- The Applicant had earned no goodwill in such a short duration.
- There was no dishonest deception by the Respondent for passing off or to divert the business of the Applicant.
- The products of the Applicant and the Respondent were different. The trade channels were different. There was no evidence of any confusion caused in the mind of the consumers.
- The products of the Applicant and the Respondent were used for different purposes, and the visual appearance of the products was different.
Aggrieved by the decision, Cutis Biotech filed the appeal at the Bombay High Court. The Bench systematically perused the three-prong test laid down for passing-off, analyzing the submissions given by the two companies.
- The Bench, analyzing the prior usage factor, after evaluation of the evidence on record, couldn’t concur with the Applicant’s claims of being the prior user of the trademark. The Bench was convinced by the submissions of the Respondent who placed on record inter-departmental communications pertaining to the mark; the traction they got through announcements of collaborations and affiliations, and advertisements; monthly production of 60 million doses and supply of 48 million doses to the Government of India, along with various licenses garnered for the manufacturing of the same. It conclusively, therefore, held:
“After evaluating the evidence on record, we find that Serum Institute had coined the word ‘Covishield’ and took substantial steps towards its development and manufacture. Thus, there is adequate and convincing material on record to demonstrate the prior adoption of the mark by Serum Institute. There is no perversity in the finding that Cutis Biotech cannot claim to be a prior user of ‘Covishield’.”
Further, while adjudicating over the goodwill of the two parties, the Court did not find sufficient material to establish goodwill in favor of the Applicant’s use of the trademark.
- Thereafter, the Bench deliberated over any likelihood of deception and confusion between the two parties’ products and practices, which is adjudged based on the minds of the customers of average intelligence and imperfect recollection. The Applicant contended that since there was a trade connection between the two parties, who function in the same industry and markets, it is immaterial that their trade channels differ, and that there existed a likelihood of confusion and deception between the two.
Concurring with the District Court, and rejecting the contentions of the Applicant, the Bench held that the products of the companies were visually different; that they function in different markets and channels- with the Applicant selling over-the-counter, while the Respondent administering the said vaccines through the Government itself.
“The administration of vaccine through injection is well known. It will be too farfetched to hold that there will be confusion in the average consumers’ minds between the use of a trademark in a Government administered vaccine at designated places and over-the-counter sanitizer products.”
- Finally, adjudicating over the damage suffered or the likelihood of the same due to the alleged passing off, the Court emphasized the combined impact of the three-prong test, and the factor pertaining to lose or potential injury must be observed in context to both, the prior usage and goodwill. Therefore, the Bench held that since the Respondent is the prior user of the mark and has acquired goodwill and because of that consumers are not consciously purchasing the goods of the Applicant, it cannot be considered as a case of passing off by the Respondent.
The Court, however, did state that owing to the large-scale sale and manufacturing of the vaccine by the Respondent, along with the amount spent its development and research, the balance of convenience rests in favor of the Respondent, who will face a serious impact if the injunction is granted against them.
The Court, dismissing the appeal, and owing to the reasoning and rationale it laid before the concerned parties, concluded its decision stating the following:
“A temporary injunction directing Serum Institute to discontinue the use of mark ‘Covishield’ for its vaccine will cause confusion and disruption in the Vaccine administration program of the State. In this case, thus, the grant of an injunction would have large scale ramifications traversing beyond the parties to the suit.”
Author: Kushagra Jain – a third-year law student of Symbiosis Law School, Noida, intern at Khurana & Khurana, Advocates and IP Attorneys. In case of any queries please contact/write back to us at email@example.com.
 APPEAL FROM ORDER NO. 53 OF 2021